6 results about "Asthma model" patented technology

The invention discloses a budesonide-loaded ginseng vesicle delivery system and a construction method and application thereof, and belongs to the technical field of plant-derived nano-drug delivery systems. According to the delivery system, nano-vesicles from ginseng are taken as carriers, and budesonide is entrapped to form a BUD-coated GDNPs compound. The delivery system can synergistically enhance the anti-inflammatory effect of budesonide, significantly alleviate airway inflammation of asthma model animals, reduce side effects such as blood glucose disorder and the like caused by high-dose budesonide, and has excellent biological safety. The delivery system provided by the invention can be used for clinical treatment of asthma, is especially suitable for patients who need to use glucocorticoid for a long time, solves the technical problems of low bioavailability and obvious side effects of traditional budesonide, and has important clinical application value and industrialization prospect.

This invention provides a traditional Chinese medicine composition for treating or improving asthma, relating to the field of traditional Chinese medicine pharmaceutical technology. The composition comprises the following raw materials: Inula japonica, Bambusa textilis, Lysimachia christinae, Rutaecarpa, Ligusticum striatum, Pyrrosia lingua, Chaenomeles speciosa, Dioscorea hypoglauca, Atractylodes lancea, walnut kernel, maltose, Citronella arvense, and Glycyrrhiza uralensis. In this invention, each ingredient in the composition fulfills its specific function, addressing both the symptoms of asthma (phlegm and qi stagnation, and upward flow of lung qi) and the underlying causes (spleen strengthening, kidney tonification, and liver soothing). This achieves the combined effects of dispelling wind and clearing the lungs, resolving phlegm and descending rebellious qi, strengthening the spleen and resolving dampness, warming the kidneys and promoting qi circulation, and regulating liver qi. It treats both the symptoms and the root cause. This invention's composition effectively inhibits airway inflammation in asthma model mice, improves clinical symptoms, and demonstrates significant therapeutic effects. The composition exhibits a high overall effective rate in treating asthma, with particular advantages in alleviating clinical symptoms and improving lung function in asthma patients.

The invention belongs to the technical field of biological medicines, and relates to application of an interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation, in particular to application of the interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation induced by ozone exposure. According to the application disclosed by the invention, comprehensive research experiments are adopted, the intervention treatment of the IL-33 antibody is implemented by constructing an asthma model and utilizing an ozone-induced asthma exacerbation model, and the pathophysiological action of the IL-33 antibody in relieving ozone-induced asthma exacerbation is comprehensively disclosed. Experimental results show that the IL-33 antibody can relieve the conditions of asthma mouse lung dysfunction, lung tissue inflammatory cell infiltration and immune cell imbalance in lung tissue caused by ozone exposure. The invention provides a new perspective for the treatment of asthma, and provides a scientific basis and practical value for developing a novel and effective asthma prevention and treatment strategy. The traditional Chinese medicine composition is expected to improve the living quality of asthma patients and reduce health risks caused by environmental pollutants, and has important clinical significance and social value.

This invention provides the use of a trisaccharide compound with a core structure of Glc(1→4)IdoA(1→4)GlcNS in the preparation of a drug for treating or preventing asthma. This compound can reduce lung inflammation in asthma model mice, reduce mucus production in the trachea, and effectively improve ventilation.

The invention discloses a preparation method and application of a traditional Chinese medicine spray for treating asthma, and belongs to the technical field of traditional Chinese medicine preparations. The stability problem of the traditional Chinese medicine spray is systematically solved through the synergistic effect of alcohol precipitation impurity removal, volatile oil clathration, pH regulation and control and the ternary stabilizer. Pharmacodynamic studies show that the spray can remarkably reduce the inflammatory factor level of asthma model mice and prolong the incubation period of asthma inducing of guinea pigs, has the effect better than that of oral granules, takes effect quickly and is suitable for quick relief in the acute attack period of asthma.

This invention relates to the field of traditional Chinese medicine (TCM) technology, and particularly to the application of TCM compositions in the preparation of drugs for the prevention and treatment of asthma. The TCM composition includes Astragalus membranaceus, Eupolyphaga sinensis, Morus alba root bark, Fritillaria cirrhosa, Perilla frutescens seed, Lepidium apetalum seed, Prunus armeniaca seed, Pheretima aspergillum, Ephedra sinica, and Clematis chinensis. Experiments show that the TCM composition provided by this invention can effectively improve airway hyperresponsiveness, reduce lung resistance, and enhance dynamic lung compliance in asthma model animals. Simultaneously, it can significantly reduce the content of pro-inflammatory factors IL-4 and IL-13 in the bronchoalveolar lavage fluid of asthma models, alleviate airway inflammation, and relieve asthma pathological symptoms. It can stably exert its effect in preventing and treating asthma, and its efficacy is stable and its safety is good. It can be further developed into a drug for the prevention and treatment of asthma and has good clinical application prospects.